Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Study Details
Study Description
Brief Summary
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions:
-
What are the demographic and clinical characteristics of metastatic prostate cancer patients?
-
How are metastatic prostate cancer patients currently treated and how effective are these treatments?
-
How does the development of castration-resistance affect patient outcomes?
-
What is the economic burden of metastatic prostate cancer?
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC)
|
Drug: degarelix
mCSPC
Drug: goserelin
mCSPC
Drug: leuprorelin
mCSPC
Drug: triptorelin
mCSPC
|
Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC)
|
Drug: abiraterone
mCRPC
Drug: enzalutamide
mCRPC
Drug: docetaxel
mCRPC
Drug: apalutamide
mCRPC
Drug: cabazitaxel
mCRPC
Drug: Radium-223
mCRPC
Drug: Lutetium-177
mCRPC
|
Outcome Measures
Primary Outcome Measures
- Characteristics of Metastatic Cancer Patients [up to 12 years]
Demographical and clinical variables of patients will be summarized
- Number of treatments received for metastatic prostate cancer [up to 12 years]
- Overall Survival (OS) [up to 12 years]
- Time to next treatment (TTNT) [up to 12 years]
Secondary Outcome Measures
- Time of disease progression from castration sensitive to castration resistant [up to 12 years]
- Identify factors associated with disease progression to castration resistant [Up to 12 years]
- The number of patients per treatment type [up to 12 years]
- Incidence of metastatic prostate cancer (mPC) [Up to 12 years]
- Incidence of metastatic castration sensitive prostate cancer (mCSPC) [up to 12 years]
- Incidence of metastatic castration resistant prostate cancer (mCRPC) [up to 12 years]
- Health Care resource utilization (HCRU): number of outpatient clinic visits, hospitalization and hospital inpatient days [up to 12 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022
-
Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC)
-
Detection of metastatic prostate cancer
Exclusion Criteria:
-
Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014
-
Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- C3441057
- PrCa-RWD